ID3 and cancer: In line with the results obtained in other cancer models that we tested, AGX51 caused a depletion of the ID1 and ID3 proteins in the pancreatic cancer cell line 806, starting at a dose between 4 and 20 μM (Fig. 3a) with ID3 showing slightly less sensitivity as observed in other cellular and biophysical assays48.